Orionis Biosciences, a privately held, clinical‑stage life sciences company focused on discovery, design and development of precision medicines, has appointed Dr. Giulio Draetta, M.D., Ph.D., as Chief Strategy Officer.

Draetta joins Orionis as the company advances and broadens its portfolio across molecular glues, conditionally active cytokines, immune cell engager therapeutic modalities and multiple next‑generation technology platforms.

“Giulio is a renowned, world-class scientist and biopharma leader with extensive expertise in medical sciences, drug discovery, clinical translation and global partnerships,” said Niko Kley, Ph.D., founder and CEO of Orionis Biosciences. “With a unique combination of scientific acumen and translational and strategic vision, Giulio is perfectly positioned to help guide Orionis in developing a deep pipeline of technology applications in programmable biology, oncology programs and product development opportunities including drug candidates in clinical trials.”

Experience

Draetta brings decades of oncology and translational research experience spanning academic, pharmaceutical and biotech environments. Most recently, he served as Chief Scientific Officer and Director of MD Anderson’s NCI‑Designated Comprehensive Cancer Center, where he spearheaded programs that accelerated the path from laboratory discovery to clinical solutions.

Earlier in his career, he held worldwide oncology drug discovery leadership positions at Pharmacia–Pfizer and Merck, guiding multiple therapeutic programs through clinical development and commercialization. He has also co‑founded several biotechnology ventures and has advised numerous companies and research institutions on portfolio development and scientific strategy.

“I’m highly energized by the momentum across Orionis’s innovative drug discovery, design and development platforms, and by the company’s strong commitment to redefining how traditionally elusive drug targets can be tackled, cancer vulnerabilities attacked and immune system functions modulated with high levels of precision,” said Draetta. “Orionis has created an environment that thrives on innovation and efficiency, and I look forward to working with an exceptional team to help translate breakthroughs into transformative therapies for cancer and beyond.”